Acumen Stock Financials

ABOS
 Stock
  

USD 6.12  0.40  6.99%   

You can use Acumen Pharmaceuticals fundamental data analysis to find out if markets are presently mispricing the company. We were able to break down and interpolate data for twenty-seven available fundamental indicators for Acumen Pharmaceuticals, which can be compared to its rivals. To ensure the equity is not overpriced, please confirm all Acumen Pharmaceuticals financials, including its cash and equivalents, as well as the relationship between the cash flow from operations and number of employees . Given that Acumen Pharmaceuticals has a number of shares shorted of 775.58 K, we suggest you to validate Acumen Pharmaceuticals prevailing market performance to make sure the company can sustain itself down the road. Use Acumen Pharmaceuticals to enhance the returns of your portfolios. Benchmarks are essential to demonstrate the utility of optimization algorithms. The stock experiences a very speculative upward sentiment. Check odds of Acumen Pharmaceuticals to be traded at $7.65 in 90 days.
  
With this module, you can analyze Acumen financials for your investing period. You should be able to track the changes in Acumen Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Acumen Most Recent Estimates

EPS Estimate Next Quarter
(0.25) 
Diluted Eps
1.23
EPS Estimate Current Year
(0.98) 
EPS Estimate Next Year
(1.23) 
EPS Estimate Current Quarter
(0.23) 
Earnings Share
1.23
Understanding current and past Acumen Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Acumen Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Acumen Pharmaceuticals' assets may result in an increase in income on the income statement.
Chance Of Financial Distress
Less than 23
Acumen Pharmaceuticals has less than 23 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Acumen Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Acumen Pharmaceuticals' official financial statements usually reflect Acumen Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Acumen Pharmaceuticals. For example, before you start analyzing numbers published by Acumen accountants, it's critical to develop an understanding of what Acumen Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Acumen Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acumen Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Acumen Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Acumen Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Acumen Pharmaceuticals' management to manipulate its earnings.

Acumen Pharmaceuticals Company Summary

Acumen Pharmaceuticals competes with Stemtech, Merck, General Electric, and Moderna. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS00509G2093
Business Address427 Park Street,
SectorHealthcare
IndustryBiotechnology
BenchmarkNYSE Composite
Websiteacumenpharm.com
Phone434 297 1000
CurrencyUSD - US Dollar
You should never invest in Acumen Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Acumen Stock, because this is throwing your money away. Analyzing the key information contained in Acumen Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Acumen Pharmaceuticals Key Financial Ratios

Generally speaking, Acumen Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Acumen Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Acumen Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Acumen Pharmaceuticals reports annually and quarterly.

Acumen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Acumen Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Acumen Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acumen Pharmaceuticals competition to find correlations between indicators driving Acumen Pharmaceuticals's intrinsic value. More Info.
Acumen Pharmaceuticals is number one stock in shares owned by institutions category among related companies. It is the top company in current valuation category among related companies reporting about  377,102  of Current Valuation per Shares Owned by Institutions. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Acumen Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Acumen Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Acumen Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Acumen Pharmaceuticals Systematic Risk

Acumen Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Acumen Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was two with a total number of output elements of fifty-nine. The Beta measures systematic risk based on how returns on Acumen Pharmaceuticals correlated with the market. If Beta is less than 0 Acumen Pharmaceuticals generally moves in the opposite direction as compared to the market. If Acumen Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Acumen Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Acumen Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Acumen Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
.

About Acumen Pharmaceuticals Financials

What exactly are Acumen Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Acumen Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Acumen Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Acumen Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Acumen Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Acumen Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Acumen has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Acumen Pharmaceuticals December 10, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Acumen Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Acumen Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Acumen Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Acumen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acumen Pharmaceuticals's daily price indicators and compare them against related drivers.
Downside Deviation5.09
Information Ratio0.0244
Maximum Drawdown113.83
Value At Risk(7.59)
Potential Upside6.49
Please continue to Trending Equities. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for analysis

When running Acumen Pharmaceuticals price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
234.1 M
Return On Assets
(0.11) 
Return On Equity
(0.18) 
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Acumen Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.